SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
2,878.00    130.00 (4.73%)
Bid:
2,846.00
Ask:
2,862.00
Spread: 16.00 (0.562%)
Market Cap: £1.59b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Acquisition

1 May 2015 07:00

RNS Number : 9497L
Oxford Instruments PLC
01 May 2015
 



 

Release date: 1 May 2015

 

Oxford Instruments plc

Acquisition of Medical Imaging Resources, Inc.

 

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today announces the acquisition of Medical Imaging Resources, Inc. (MIR).

 

Founded in 1990 in Ann Arbor Michigan by CEO John Vartanian, MIR specialises in the build, lease and service of mobile medical imaging labs ("mobiles").

 

The mobile labs are built in MIR's factory, with Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) systems from Siemens, GE, Philips and Toshiba. These are leased to customers across the USA. MIR is also responsible for servicing its mobiles. Customers include hospitals and clinics that need additional capacity or that wish to trial MRI or CT machines without committing to the infrastructure and cost associated with a permanent unit.

 

MIR will form a part of OIHealthcare, within the Group's Service sector, which already services GE MRI and CT machines in the USA. There are a number of synergies with OIHealthcare:

 

· This will be a significant step to making OIHealthcare a multi-skilled independent service provider able to support large individual service contracts;

· Access to OIHealthcare's parts and its purchasing power for complete systems will lower MIR's operating costs;

· There will be overheads savings in those areas where duplication is eliminated;

· MIR currently sub-contracts a significant portion of the service work for its mobiles. OIHealthcare staff are located in numerous states and once trained will take over the work and will be able to bring the margin in-house.

 

Consideration, which will be satisfied from existing facilities, comprises $10.4 million (c. £6.8 million) on completion followed by a further $10.1 million (c. £6.6 million) earn-out payable one year later. MIR has approximately $3.0 million (c. £2.0 million) net debt at completion.

 

In the year to 31 December 2014, MIR had sales of $16.6 million (c. £10.8 million), profit before tax of $2.8 million (c. £1.8 million) and EBITDA of $5.6 million (c. £3.6 million). At 31 December 2014, MIR had gross assets of $9.4 million (c. £6.1 million).

 

 

 

Jonathan Flint (Chief Executive) and Kevin Boyd (Finance Director) will host a conference call for analysts and investors on this announcement at 9:30 am (UK time), today 1 May. To join the call, please use the dial-in numbers below:

 

Dial: +44 (0)20 3139 4830

PIN: 89662683#

 

 

 

- Ends -

 

Enquiries:

 

 

Oxford Instruments plc Tel: 01865 393200

Jonathan Flint, Chief Executive

Kevin Boyd, Group Finance Director

 

MHP Tel: 020 3128 8100

Rachel Hirst / Jack Holden

 

Issued for and on behalf of Oxford Instruments plc

 

 

 

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments designs, supplies and supports high-technology tools and systems with a focus on research and industrial applications. Innovation has been the driving force behind Oxford Instruments' growth and success for over 50 years, and its strategy is to effect the successful commercialisation of these ideas by bringing them to market in a timely and customer-focused fashion.

The first technology business to be spun out from Oxford University, Oxford Instruments objective is to be the leading provider of new generation tools and systems for the research and industrial sectors with a focus on nanotechnology. Its key market sectors include nano-fabrication and nano-materials. The company's strategy is to expand the business into the life sciences arena, where nanotechnology and biotechnology intersect.

This involves the combination of core technologies in areas such as low temperature, high magnetic field and ultra high vacuum environments; Nuclear Magnetic Resonance; x-ray, electron, laser and optical based metrology; atomic force microscopy; optical imaging; advanced growth, deposition and etching.

Oxford Instruments aims to pursue responsible development and deeper understanding of our world through science and technology. Its products, expertise, and ideas address global issues such as energy, environment, security and health.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQEAFLEDSDSEAF
Date   Source Headline
3rd Aug 202012:07 pmRNSSecond Price Monitoring Extn
3rd Aug 202012:02 pmRNSPrice Monitoring Extension
30th Jul 202012:08 pmRNSSecond Price Monitoring Extn
30th Jul 202012:03 pmRNSPrice Monitoring Extension
24th Jul 202012:07 pmRNSSecond Price Monitoring Extn
24th Jul 202012:02 pmRNSPrice Monitoring Extension
23rd Jul 202012:07 pmRNSSecond Price Monitoring Extn
23rd Jul 202012:02 pmRNSPrice Monitoring Extension
22nd Jul 202012:08 pmRNSSecond Price Monitoring Extn
22nd Jul 202012:02 pmRNSPrice Monitoring Extension
21st Jul 20204:10 pmPRNHolding(s) in Company
16th Jul 202012:07 pmRNSSecond Price Monitoring Extn
16th Jul 202012:02 pmRNSPrice Monitoring Extension
14th Jul 20201:43 pmPRNNotice of AGM
14th Jul 202012:02 pmRNSPrice Monitoring Extension
13th Jul 20201:35 pmPRNDirector/PDMR Shareholding
9th Jul 202010:13 amPRNTotal Voting Rights
6th Jul 202012:02 pmRNSPrice Monitoring Extension
2nd Jul 20203:50 pmPRNBlocklisting - Interim Review
2nd Jul 20209:37 amPRNHolding(s) in Company
25th Jun 20209:55 amPRNHolding(s) in Company
25th Jun 20209:34 amPRNHolding(s) in Company
11th Jun 202012:07 pmPRNDirector/PDMR Shareholding
10th Jun 202012:02 pmRNSPrice Monitoring Extension
9th Jun 20207:00 amRNSAppointment of Independent Non-Executive Director
9th Jun 20207:00 amRNSPreliminary Results
2nd Jun 202010:41 amPRNTotal Voting Rights
18th May 202012:07 pmRNSSecond Price Monitoring Extn
18th May 202012:02 pmRNSPrice Monitoring Extension
12th May 20201:32 pmPRNDirector/PDMR Shareholding
7th May 20205:07 pmPRNTotal Voting Rights
5th May 202012:02 pmRNSPrice Monitoring Extension
4th May 20208:27 amPRNDisclosure of Rights Attached to Equity Shares
1st May 202012:07 pmRNSSecond Price Monitoring Extn
1st May 202012:02 pmRNSPrice Monitoring Extension
30th Apr 202012:07 pmRNSSecond Price Monitoring Extn
30th Apr 202012:02 pmRNSPrice Monitoring Extension
27th Apr 202012:03 pmRNSPrice Monitoring Extension
24th Apr 202012:02 pmRNSPrice Monitoring Extension
21st Apr 202012:02 pmRNSPrice Monitoring Extension
16th Apr 202010:51 amPRNDirector/PDMR Shareholding
3rd Apr 202012:39 pmPRNDirector Declaration
1st Apr 202012:03 pmRNSPrice Monitoring Extension
1st Apr 202010:06 amPRNHolding(s) in Company
30th Mar 20207:00 amRNSSuspension of Interim Dividend
20th Mar 202012:07 pmRNSSecond Price Monitoring Extn
20th Mar 202012:02 pmRNSPrice Monitoring Extension
19th Mar 20204:41 pmRNSSecond Price Monitoring Extn
19th Mar 20204:36 pmRNSPrice Monitoring Extension
18th Mar 20207:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.